Every indexed document

LLC and or its affiliates make a market in the stock of GW Pharmaceuticals Plc

and (ii) no part of his or her compensation was

economic or market conditions. Commentaries produced by Cowen Washington Research Group are not

much work and change still needs to occur in order for this industry to

we believe this will be an attractive option for

18 of whom completed the 12 week treatment. At 12 weeks

and the company is testing numerous other cannabinoids. GW’s CBDV

while the p-values suggest that CBD has activity

headache (7% CBD vs. 8.9% placebo) and somnolence

many of which were other scales measuring functionality and

and reached statistical significance in patients taking

placebo-controlled exploratory trial in 88 patients with schizophrenia

although patients on clobazam (51%) had some additional

patients were on an average of three AEDs

it did note that ""the effect of concomitant AEDs on

and 37% for Epidiolex vs. 10% for placebo

p=0.0052. The median reduction in total seizures was 29% for Epidiolex vs.

Epidiolex achieved a highly statistically significant

patients were taking ~3 AEDS after previously

and a Phase II/III trial in infantile spasms. The first